Entellus Medical, Inc. (ENTL) VP Stephen R. Paidosh Sells 25,000 Shares
Entellus Medical, Inc. (NASDAQ:ENTL) VP Stephen R. Paidosh sold 25,000 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $17.54, for a total transaction of $438,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Entellus Medical, Inc. (ENTL) traded up 0.06% during mid-day trading on Thursday, reaching $17.68. 132,646 shares of the company’s stock were exchanged. The stock’s market cap is $448.56 million. Entellus Medical, Inc. has a 52-week low of $12.31 and a 52-week high of $22.57. The stock’s 50-day moving average is $17.47 and its 200-day moving average is $15.46.
Entellus Medical (NASDAQ:ENTL) last announced its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). The business had revenue of $22.10 million during the quarter, compared to the consensus estimate of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The company’s revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.27) EPS. On average, equities analysts expect that Entellus Medical, Inc. will post ($1.61) EPS for the current year.
Several analysts recently issued reports on ENTL shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $21.00 price objective on shares of Entellus Medical in a report on Tuesday, August 22nd. BidaskClub raised shares of Entellus Medical from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Canaccord Genuity set a $18.00 price objective on shares of Entellus Medical and gave the stock a “hold” rating in a report on Monday, May 22nd. Finally, ValuEngine downgraded shares of Entellus Medical from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 23rd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Entellus Medical presently has a consensus rating of “Hold” and an average target price of $21.71.
Several institutional investors have recently made changes to their positions in ENTL. Frontier Capital Management Co. LLC bought a new stake in shares of Entellus Medical in the first quarter valued at about $6,464,000. William Blair Investment Management LLC boosted its position in shares of Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock valued at $5,387,000 after acquiring an additional 355,388 shares during the period. Tekla Capital Management LLC bought a new stake in shares of Entellus Medical in the second quarter valued at about $5,655,000. Nicholas Company Inc. boosted its position in shares of Entellus Medical by 1,052.3% in the second quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock valued at $4,101,000 after acquiring an additional 226,190 shares during the period. Finally, Kingdon Capital Management L.L.C. boosted its position in shares of Entellus Medical by 79.6% in the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock valued at $6,215,000 after acquiring an additional 199,615 shares during the period. 70.41% of the stock is owned by institutional investors.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.